4D Pharma (LON:DDDD) Trading 5% Higher
4D Pharma (LON:DDDD) Trading 5% Higher
4D pharma plc, together with its subsidiaries, develops live biotherapeutic products (LBPs) in the United Kingdom. The company develops therapeutic candidates, including MRx0518 for the treatment of cancer and immune-oncology diseases; MRx-4DP0004 for the treatment of asthma; MRx0029 and MRx0005 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn's disease.4D pharma plc (LON:DDDD – Get Rating)'s share price traded up 5% on Tuesday . The stock traded as high as GBX 16.86 ($0.20) and last traded at GBX 16.66 ($0.20). 912,370 shares were traded during mid-day trading, a decline of 69% from the average session volume of 2,957,490 shares. The stock had previously closed at GBX 15.86 ($0.19).
4D pharma plc（LON: DDDD — 获取评级）的股价周二上涨了5％。该股的交易价格高达16.86英镑（0.20美元），最后一次交易价格为16.66英镑（0.20美元）。午盘交易中交易了912,370股，较平均交易日交易量2957,490股下跌了69％。该股此前收于15.86英镑（0.19美元）。
4D pharma Stock Performance
4D 制药股票表现
The company has a debt-to-equity ratio of 39.50, a current ratio of 5.21 and a quick ratio of 4.72. The firm has a market cap of £30.04 million and a price-to-earnings ratio of -1.08. The company has a fifty day moving average price of GBX 16.66 and a two-hundred day moving average price of GBX 27.35.
该公司的债务与权益比率为39.50，流动比率为5.21，速动比率为4.72。该公司的市值为30004万英镑，市盈率为-1.08。该公司的五十天移动平均价格为16.66英镑，两百天移动平均线价格为27.35英镑。
4D pharma Company Profile
4D 制药公司简介
(Get Rating)
（获取评分）
4D pharma plc, together with its subsidiaries, develops live biotherapeutic products (LBPs) in the United Kingdom. The company develops therapeutic candidates, including MRx0518 for the treatment of cancer and immune-oncology diseases; MRx-4DP0004 for the treatment of asthma; MRx0029 and MRx0005 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn's disease.
4D pharma plc及其子公司在英国开发活体生物治疗产品（LBP）。该公司开发的候选疗法包括用于治疗癌症和免疫肿瘤学疾病的mrx0518；用于治疗哮喘的mrx-4dp0004；用于治疗中枢神经系统疾病的mrx0029和mrx0005；用于肠易激综合征的Blautix；以及用于小儿克罗恩病的Thetanix。
Featured Articles
精选文章
- 3 Alzheimer Stocks to Buy as the Race for a Cure Heats Up
- Don't Forget About These Cheap, Fundamentally Strong Tech Stocks
- Bellwether RPM International Pops On Results
- Rivian Checks Off Boxes, But Still Needs a Lot to Go Right
- Hot Potato: Lamb Weston Stock Confirms a Top
- 随着治疗竞赛的升温，有3只阿尔茨海默氏症股票值得买入
- 别忘了这些便宜、基本上强劲的科技股
- Bellwether RPM 国际业绩大放异彩
- Rivian 勾选了方框，但还需要做很多事情才能做好
- 热土豆：兰姆·韦斯顿股票确认涨至顶点
Receive News & Ratings for 4D pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 4D pharma and related companies with MarketBeat.com's FREE daily email newsletter.
接收 4D pharma Daily 的新闻和评级 -在下面输入您的电子邮件地址，即可通过Marketbeat.com的免费每日电子邮件时事通讯接收4D制药及相关公司的最新新闻和分析师评级的简要每日摘要。
译文内容由第三方软件翻译。
